OSL · TRMED.OL
Thor Medical ASA
NOK 4.15-NOK 0.06 (-1.54%)
Thor Medical ASA’s quoted price sits in the lower half of its reported 52-week range, 41.71% below the high.
Loading market information…
OSL · NYKD.OL · NOK
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 08:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · NOK. Historical prices are not a forecast.
Nykode Therapeutics AS’s quoted price sits in the lower half of its reported 52-week range, 42.12% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Nykode Therapeutics AS’s next earnings report is currently expected on Nov 25, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nykode Therapeutics AS’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
Latest available per-share figures in NOK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:46 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| NOK 137.00K-94.75% vs estimate |
| Q4 2024 | Feb 26, 2025 | -NOK 0.24+55.3% vs estimate | NOK 77.12M+412.35% vs estimate |
|---|
| Q3 2024 | Nov 27, 2024 | -NOK 0.32-538.94% vs estimate | NOK 6.25M-79.76% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NOK 4.15-NOK 0.06 (-1.54%)
Thor Medical ASA’s quoted price sits in the lower half of its reported 52-week range, 41.71% below the high.
NOK 21.40NOK 0.00 (0.0%)
ArcticZymes Technologies ASA’s quoted price sits in the lower half of its reported 52-week range, 26.21% below the high.
NOK 38.60-NOK 0.90 (-2.28%)
Gentian Diagnostics AS’s quoted price sits in the lower half of its reported 52-week range, 35.67% below the high.
NOK 7.74+NOK 0.24 (+3.2%)
Lytix Biopharma AS’s quoted price sits in the lower half of its reported 52-week range, 34.96% below the high.
NOK 1.30-NOK 0.01 (-0.38%)
Hofseth BioCare ASA’s quoted price sits in the lower half of its reported 52-week range, 37.14% below the high.
NOK 4.50NOK 0.00 (0.0%)
ContextVision AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 22.15% below the high.
NOK 11.20+NOK 0.20 (+1.82%)
Navamedic ASA’s quoted price sits in the lower half of its reported 52-week range, 57.74% below the high.
NOK 2.28+NOK 0.08 (+3.64%)
Arctic Bioscience AS’s quoted price sits in the lower half of its reported 52-week range, 45.71% below the high.
